“This proposal to spur generic drug competition is one important example of the “smart savings” we need to roll back the sequester and meet the nation’s fiscal challenges.
Greater generic use can generate billions in federal savings without shifting costs to consumers, states or the private sector. Recommendations to close the REMS loopholes, promote medication adherence, promote biologic drug competition, reform payment for Medicare Part B drugs, and incentivize greater generic use by state Medicaid programs enjoy support from the provider, payer, and consumer organizations that make up the National Coalition on Health Care and were important elements of our NCHC Plan for Health and Fiscal Policy released last November.”